Pain Market Draws New NDA Submissions
This article was originally published in The Pink Sheet Daily
Executive Summary
Pharma giant J&J and specialty drug company Javelin Pharmaceuticals are both seeking NDAs for new formulations of already approved pain medications.
You may also be interested in...
J&J Wins Nucynta ER Approval, Targets Chronic Pain Market
The company plans a push for the extended release formulation of its opioid medication.
J&J Wins Nucynta ER Approval, Targets Chronic Pain Market
The company plans a push for the extended release formulation of its opioid medication.
As Opioid REMS Meeting Nears, FDA Notes Worry About Shifting Use To Different Class
In NEJM editorial, FDA's Woodcock suggests "unintended consequences" of any risk management plan for the pain products.